Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit.
Journaljournal of allergy and clinical immunology10.228Date
2020 Jun 04
4 months ago
Journal Article
2020-Aug / 146 : 244-249
Pepper AN 1, Assa'ad A 2, Blaiss M 3, Brown E 4, Chinthrajah S 5, Ciaccio C 6, Fasano MB 7, Gupta R 8, Hong N 9, Lang D 10, Mahr T 11, Malawer E 12, Roach A 9, Shreffler W 13, Sicherer S 14, Vickers K 9, Vickery BP 15, Wasserman R 16, Yates K 17, Casale TB 18
  • 2. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • 3. Medical College of Georgia at Augusta University, Augusta, Ga.
  • 4. Food Equality Initiative, Kansas City, Mo.
  • 5. Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, Calif.
  • 6. The University of Chicago, Department of Pediatrics, Chicago, Ill.
  • 7. University of Iowa Carver College of Medicine, Iowa City, Iowa.
  • 8. Center for Food Allergy and Asthma Research, Northwestern University Feinberg School of Medicine, Chicago, Ill; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill.
  • 9. FARE (Food Allergy Research & Education), McLean, Va.
  • 10. Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
  • 11. Gundersen Health System, La Crosse, Wis.
  • 12. AllergyStrong, McClean, Va.
  • 13. Food Allergy Center, Departments of Pediatrics and Medicine, Massachusetts General Hospital, Boston, Mass.
  • 14. the Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • 15. Food Allergy Center at Emory + Children's, Atlanta, Ga.
  • 16. Allergy Partners of North Texas, Dallas.
  • 17. Latitude Food Allergy Care, Redwood City, Calif.
  • 18. Food Allergy Research & Education (FARE), University of South Florida, Tampa, Fla. Electronic address: [email protected]
Food allergy is a major health problem affecting 5% to 10% of the population in developed nations, including an estimated 32 million Americans. Despite the large number of patients suffering from food allergies, up until the end of January 2020, no treatment for food allergies had been approved by the US Food and Drug Administration. The only options were avoidance of food allergen triggers and acute management of allergic reactions. A considerable body of data exists supporting oral immunotherapy (OIT) as a promising, novel treatment option, including that for the now Food and Drug Administration-approved peanut OIT product Palforzia (Aimmune Therapeutics, Brisbane, Calif). However, data for long-term quality-of-life improvement with OIT varies, depending on the measures used for analysis. Like many therapies, OIT is not without potential harms, and burdens, and the evaluation of patient-specific risk-benefit ratio of food OIT produces challenges for clinicians and patients alike, with many unanswered questions. Food Allergy Research & Education organized the Oral Immunotherapy for Food Allergy Summit on November 6, 2019, modeled after the PRACTALL sessions between the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology to address these critical issues. Health care providers, patient representatives, researchers, regulators, and food allergy advocates came together to discuss OIT and identify areas of common ground as well as gaps in existing research and areas of uncertainty and disagreement. The purpose of this article was to summarize that discussion and facilitate collaboration among clinicians and patients to help them make better-informed decisions about offering and accepting OIT, respectively, as a therapeutic option.
Keywords: Food allergy Oral immunotherapy Peanut allergy
J Allergy Clin Immunoljournal of allergy and clinical immunology
LocationUnited States

No Data

© 2017 - 2020 Medicgo
Powered by some medical students